# Targeting Bad Cells with Toxic Antibodies for Cancer and Autoimmune Disease > This patent describes special antibodies equipped with a toxic payload that specifically seek out and bind to unique markers on diseased cells, like cancer or autoimmune cells, to destroy them. - **Patent:** US 20210205465 - **Original title:** Aberrant cell-restricted immunoglobulins provided with a toxic moiety - **Owner:** Apo T BV - **Status:** Active - **Times cited:** 0 - **Field:** biotech, pharmaceutical, gene_editing ## What it does This patent describes a specialized antibody, called an immunoglobulin, that carries a toxic substance, or 'toxic moiety' (Claim 1). This antibody is designed to specifically attach to a unique flag, an 'MHC-peptide complex,' that is found mostly on 'aberrant cells' – which are diseased cells like cancer or those involved in autoimmune conditions (Claim 1). The toxic substance can be chemically attached to the antibody or even built into it at the genetic level as a 'fusion protein' (Claims 6, 7). The goal is to deliver this toxic payload directly to the aberrant cells, potentially even getting the toxin inside them (Claim 10), to treat diseases like cancer (Claim 11). For example, an antibody could be engineered to find a specific MHC-peptide complex on a melanoma cell, then deliver a cell-killing drug directly to that cell. ## What it does NOT cover - Does not cover immunoglobulins that do not have a toxic moiety attached to them. - Does not cover toxic therapies where the toxic agent is not specifically delivered by an immunoglobulin. - Does not cover immunoglobulins that target cells by binding to something other than an MHC-peptide complex. - Does not cover immunoglobulins that bind to MHC-peptide complexes that are equally common on both healthy and diseased cells. - Does not cover immunoglobulins that target aberrant cells but are not specifically designed to bind to an MHC-peptide complex. ## The clever bit The novelty lies in precisely targeting 'aberrant cells' using an immunoglobulin that binds to an 'MHC-peptide complex' that is *preferentially* found on these diseased cells, and then delivering a 'toxic moiety' directly to them. This allows for highly specific destruction of harmful cells while sparing healthy ones. ## Real-world examples 1. Antibody-Drug Conjugates (ADCs) in cancer therapy 2. Targeted immunotherapies for specific tumor types 3. Experimental treatments for autoimmune diseases using targeted cell depletion ## Why it matters This technology aims to create highly targeted therapies for serious diseases like cancer and autoimmune disorders. By specifically delivering a toxic payload to aberrant cells, it seeks to minimize harm to healthy tissues, potentially reducing severe side effects often associated with traditional treatments like chemotherapy. This precision targeting could lead to more effective and safer treatment options for patients. ## Frequently asked questions ### What does Targeting Bad Cells with Toxic Antibodies for Cancer and Autoimmune Disease cover? This patent describes special antibodies equipped with a toxic payload that specifically seek out and bind to unique markers on diseased cells, like cancer or autoimmune cells, to destroy them. ### Who owns patent US 20210205465? This patent is owned by Apo T BV. ### When does this patent expire? This patent is expected to expire on January 11, 2041, when the invention enters the public domain. ### What problem does this patent solve? This technology aims to create highly targeted therapies for serious diseases like cancer and autoimmune disorders. By specifically delivering a toxic payload to aberrant cells, it seeks to minimize harm to healthy tissues, potentially reducing severe side effects often associated with traditional treatments like chemotherapy. This precision targeting could lead to more effective and safer treatment options for patients. ### What does this patent NOT cover? Does not cover immunoglobulins that do not have a toxic moiety attached to them. **Full plain-English explainer:** https://patentbrief.org/patent/us/20210205465/aberrant-cell-restricted-immunoglobulins-provided-with-a-toxic-moiety **Original patent:** https://patents.google.com/patent/US20210205465 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [How Antibodies Can Force Cancer Cells to Self-Destruct](https://patentbrief.org/patent/us/7807153/avastin-chemotherapy) — Genentech's patent on specific antibodies that bind to the Apo-2 receptor to trigger programmed cell death in cancer cells. - [How to Build Smaller, Synthetic Antibody-Like Molecules for Medicine](https://patentbrief.org/patent/us/5455030/immunotheraphy-using-single-chain-polypeptide-binding-molecules) — This patent describes a way to create small, single-chain proteins that mimic the binding power of full-sized antibodies to deliver medicine more effectively. - [Making Hybrid Antibodies from Different Animals](https://patentbrief.org/patent/us/4816567/recombinant-antibody-production-in-cho-cells) — This patent describes how to create new, engineered antibodies by combining parts of antibodies from two different animal species, then growing them in a lab. - [How Scientists Create Human-Friendly Antibodies for Medicine](https://patentbrief.org/patent/us/5585089/remicade-infliximab) — This patent describes a method for modifying mouse antibodies so human immune systems accept them as their own, allowing them to be used as powerful, long-lasting medical treatments. - [How Genentech's Antibody Targets Cancerous B Cells](https://patentbrief.org/patent/us/9845355/tecentriq-atezolizumab) — This patent describes a specific humanized antibody designed to bind to a protein called CD79b, which is found on the surface of certain cancer cells.